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Abstract
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic or episodic
inflammation in many different organ systems, activation of leukocytes and production of pro-inflammatory
cytokines. The heterodimer of the cytosolic calcium-binding proteins S100A8 and S100A9 (S100A8/A9) is secreted
by activated polymorphonuclear neutrophils (PMNs) and monocytes and serves as a serum marker for several
inflammatory diseases. Furthermore, S100A8 and S100A9 have many pro-inflammatory properties such as binding
to Toll-like receptor 4 (TLR4). In this study we investigated if aberrant cell surface S100A8/A9 could be seen in SLE
and if plasmacytoid dendritic cells (pDCs) could synthesize S100A8/A9.
Methods: Flow cytometry, confocal microscopy and real-time PCR of flow cytometry-sorted cells were used to
measure cell surface S100A8/A9, intracellular S100A8/A9 and mRNA levels of S100A8 and S100A9, respectively.
Results: Cell surface S100A8/A9 was detected on all leukocyte subpopulations investigated except for T cells. By
confocal microscopy, real-time PCR and stimulation assays, we could demonstrate that pDCs, monocytes and PMNs
could synthesize S100A8/A9. Furthermore, pDC cell surface S100A8/A9 was higher in patients with active disease as
compared to patients with inactive disease. Upon immune complex stimulation, pDCs up-regulated the cell surface
S100A8/A9. SLE patients had also increased serum levels of S100A8/A9.
Conclusions: Patients with SLE had increased cell surface S100A8/A9, which could be important in amplification
and persistence of inflammation. Importantly, pDCs were able to synthesize S100A8/A9 proteins and up-regulate
the cell surface expression upon immune complex-stimulation. Thus, S100A8/A9 may be a potent target for
treatment of inflammatory diseases such as SLE.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by inflammation in several organ
systems, B cell hyperactivity, autoantibodies, complement
consumption and an ongoing type I interferon (IFN) pro-
duction [1,2]. SLE patients usually have more activated
peripheral blood mononuclear cells (PBMCs) in circula-
tion than healthy individuals and there are numerous
investigations demonstrating abnormalities in different
subpopulations which illustrate the complexity of the
pathogenesis in this disease. Increased numbers of
plasma cells [3,4], HLA-DR
+ T cells [5,6] and decreased
numbers of circulating dendritic cells [7,8] have been
reported. Pro-inflammatory CD16
+ monocytes have been
described to be increased in rheumatoid arthritis but are
so far not investigated in SLE [9].
The IFN-alpha (IFNa) production in SLE is detectable
in serum [10], and over-expression of IFNa-regulated
genes, termed the type I IFN signature, has also been
demonstrated in PBMCs [11-16] as well as in platelets
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any medium, provided the original work is properly cited.[17]. In mice, type I IFNs induce lymphopenia through
redistribution of the lymphocytes [18] and there is an
inverse correlation between serum IFNa and leukocyte
count in humans [10]. SLE patients have circulating
immune complexes (ICs), which often contain RNA or
DNA [19,20]. ICs could be endocytosed by the natural
IFNa producing cells, the plasmacytoid dendritic cells
(pDCs) and induce IFNa production through Toll-like
receptor (TLR) 7 or TLR9 stimulation [21,22], which is
considered to have a key role in the pathogenesis of SLE
[23]. IFNa has many immunomodulatory functions such
as inducing monocyte maturation [24], increasing IFNa
production from NK cells [25], prolonging the survival
of activated T cells [26] and differentiating B cells to
plasma cells [27].
S100A8 and S100A9 are members of the calcium-
binding S100-protein family and are released at
inflammatory sites by phagocytes as a complex
(S100A8/A9; also called calprotectin or MRP8/14)
[28]. Several pro-inflammatory properties have been
described for the S100A8/A9 complex, such as activa-
tion of monocytes [29], amplification of cytokine pro-
duction [30], regulation of migration of myeloid
derived suppressor cells [31] and, as demonstrated
recently, a ligand for receptor for advanced glycation
end products (RAGE) and TLR4 [32]. Patients with
SLE have increased serum levels of S100A8/A9 [33,34]
and the concentration correlates with disease activity.
Here we have investigated the portion and activation
status of several leukocyte subpopulations and mea-
sured cell surface S100A8/A9 on these cells, corre-
sponding S100A8 and S100A9 mRNA expression as
well as serum levels of S100A8/A9 in healthy controls
and SLE patients to learn more about the role of these
proteins in SLE.
Materials and methods
Patients
SLE patients were recruited from an ongoing prospec-
tive control program at the Department of Rheumatol-
ogy, Skåne University Hospital, Lund, Sweden. Blood
samples were taken at their regular visits. Healthy sub-
jects, age-matched to the patients, were used as con-
trols. An overview of clinical characteristics is presented
in Tables 1 and 2. Disease activity was assessed using
SLEDAI-2K [35]. The following SLE treatments were
used at the time point of blood sampling: hydroxychlor-
oquine (n = 38), azathioprine (n = 17), mycophenolat-
mofetil (n = 11), rituximab (within the last 12 months,
n = 5), methotrexate (n = 4), cyclosporine A (n =3 ) ,
cyclophosphamide (n = 2), chloroquine phosphate (n =
1) and intravenous immunoglobulins (n =1 ) .A l l
patients fulfilled at least four American College of
Rheumatology (ACR) 1982 criteria for SLE [36]. The
study was approved by the regional ethics board (LU
378-02). Informed consent was obtained from all
participants.
Antibodies and reagents
The following antibodies and reagents were used in the
flow cytometry analysis of the patients and the healthy
volunteers: anti-CD3-Alexa 647, anti-CD4-APC-Cy7,
anti-CD19-Pacific Blue, anti-CD14-PE-Cy7 (all from
BioLegend, San Diego, CA, USA), anti-CD3-APC-Alexa
Fluor 750, anti-CD8-PE-Cy7, anti-HLA-DR-Alexa Fluor
700, anti-CD20-PE, anti-CD38-PE-Cy5, anti-CD27-Alexa
Fluor 700 (all from eBioscience, San Diego, CA, USA),
propidium iodide, anti-IgD-FITC, anti-CD16-PE-Cy5,
mouse IgG1-FITC (all from BD Biosciences Pharmingen,
San Diego, CA, USA), anti-BDCA-1-biotin, anti-BDCA-
2-PE (both from Miltenyi Biotec Inc., Auburn, CA,
USA), anti-S100A8/A9-FITC (27E10, BMA Biomedicals,
Rheinstrasse, Switzerland) and streptavidin Qdot-605
(Invitrogen, Carlsbad, CA, USA).
Table 1 Clinical characteristics of the SLE patients at the
time point of blood sampling
Characteristics SLE (n = 63) Control (n = 33)
Age, median (range), years 42 (19 to 81) 45 (24 to 79)
Female, % 94 85
Male, % 61 5
Disease duration, median
(range), years
8 (0 to 45) -
SLEDAI score, median (range) 2 (0 to 18) -
Seizure 0-
Psychosis 0-
Organic brain syndrome 0-
Visual disturbance 1-
Cranial nerve disorder 1-
Lupus headache 0-
Cerebrovascular accident 0-
Vasculitis 3-
Arthritis 8-
Myositis 1-
Kidney involvement (urinary
cast, hematuria, proteinuria or
pyuria)
14 -
Mucocutaneous activity (rash,
alopecia or mucosal ulcers)
12 -
Pleurisy 0-
Pericarditis 0-
Low complement (C3 or C4) 14 -
Anti-DNA antibodies 14 -
Fever 2-
Thrombocytopenia 1-
Leukopenia 2-
Items included in SLE disease activity (SLEDAI) are shown.
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Blood was drawn into cell preparation tubes (BD Bios-
ciences Pharmingen) and PBMCs were isolated on Lym-
phoprep™ according to manufacturer’s instructions
(Axis-Shield PoC AS, Oslo, Norway). PBMCs (1 × 10
6
cells) were incubated with 10% mouse serum in phos-
phate buffered saline pH 7.2 (PBS) at a total volume of
50 μl for 20 minutes at 4°C. The cells were washed in
PBS (200 g 2 minutes) and incubated with biotinylated
antibodies for 20 minutes at 4°C. The cells were washed
twice and then incubated for another 20 minutes at 4°C
with dye-conjugated antibodies and streptavidin-Qdot
605. Finally, the cells were washed twice and resus-
pended in 300 μl PBS before analysis in the FACSAria
(BD Biosciences Pharmingen).
Confocal microscopy
T cells, monocytes and pDCs were isolated with negative
isolation kits according to manufacturer’si n s t r u c t i o n s
(Miltenyi Biotec Inc). Neutrophils were isolated by den-
sity gradient centrifugation on Polymorphprep™ accord-
ing to the manufacturer’s protocol (Axis-Shield PoC AS).
Bc e l l sa n dm D C sw e r ei s o l a t e du s i n gaF A C S A r i ac e l l
sorter. B cells were labeled withP a c i f i cB l u e - c o n j u g a t e d
CD19 antibodies and mDCs were labeled with both
Alexa 700-conjugated HLA-DR antibodies and FITC-
conjugated BDCA-1 antibodies. Purified cells (8 × 10
4)
were fixed with 4% paraformaldehyde and permeabilized
in 0.2% TritonX-100 (Sigma, St. Louis, MO, USA) before
incubated with PE-conjugated anti-S100A8/A9 antibo-
dies (27E10, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) for 30 minutes. The cells were washed once in PBS
and transferred to a glass slide (In Vitro, Braunschweig,
Germany) by cytospin for two minutes at a speed of
1,000 g in a Shandon Cytospin 3 (Life Science Interna-
tional LTD, Cheshire, UK). The cells were analyzed in a
LSM 510 META microscope (Carl Zeiss, Göttingen,
Germany). Fluorescence was detected with pinhole set-
tings corresponding to one airy unit.
Immune complex stimulation of plasmacytoid dendritic
cells
Isolated pDCs (2 × 10
4 cells) were cultured in 100 μl
Macrophage-SFM (Invitrogen) supplemented with 20 mM
HEPES (Invitrogen), 50 μg/ml Gentamicin (Invitrogen),
2 ng/ml GM-CSF (Leukine
®; Berlex, Montville, NJ, USA)
and 500 U/ml IntronA (SP company, Innishannon, Ire-
land) and incubated for 20 h at 37°C with 5% CO2 and
97% humidity with RNA-containing ICs prepared as
described previously [37]. Briefly, anti-ribonuclear protein
(RNP)-positive sera were pooled and IgG was purified on
a protein G column (Protein G Superose HR 10/2, Phar-
macia LKB, Uppsala, Sweden). To create ICs, purified IgG
at a concentration of 0.25 mg/ml was mixed with necrotic
material from Jurkat cell supernatant at a concentration of
5% (v/v). The cells were washed and resuspended in PBS
with anti-CD123-FITC (Miltenyi Biotech) and anti-
S100A8/A9-PE (Santa Cruz Biotechnology) antibodies for
30 minutes at 4°C before analyzed by flow cytometry. The
ICs used in the experiments contained undetectable
amounts (< 40 ng/ml) of S100A8/A9 as measured by the
in-house ELISA (data not shown). As a negative control,
PE-conjugated mouse IgG1 antibodies were used.
Serum S100A8/A9 detection
For detection of S100A8/A9, microtitre plates (Maxisorp,
Nunc, Roskilde, Denmark) were coated with monoclonal
antibody MRP8/14 (27E10, BMA Biomedicals) at a con-
centration of 5 μg/ml, diluted in PBS at a volume of
100 μl/well, and incubated at 4°C over night. The 27E10
antibody detects a specific epitope of S100A8/A9 which is
not exposed on the individual subunits. Between every fol-
lowing step, the plate was washed for three times in PBS
containing 0.05% Tween 20. After blocking the plate with
1% BSA in PBS for 1 h, serum samples, diluted 1/100 in
sample buffer (0.15 M NaCl, 10 mM HEPES (Invitrogen),
1 mM CaCl2, 0.02 mM ZnCl2, 0.05% Tween 20 and 0.1%
BSA), were added at a final volume of 100 μl/well and
incubated for 2 h at room temperature under agitation.
Biotinylated anti-MRP8/14 ( A b c a m ,C a m b r i d g e ,U K ) ,
diluted 1/2000 in sample buffer, were added at a volume
of 100 μl/well, and incubated at 4°C over night. Bound
MRP8/14 antibody was detected with alkaline-phospha-
tase-labelled streptavidin (Dako, Glostrup, Denmark)
diluted 1/1000 in sample buffer. After incubation for 1 h
at room temperature under agitation, the enzymatic reac-
tion was developed with 1 mg/ml disodium-p-nitrophenyl
Table 2 Clinical characteristics of the SLE patients
(n = 63) according to ACR 1982 criteria
ACR criteria Portion of patients (%)
Malar rash 65
Discoid rash 25
Photosensitivity 67
Oral ulcers 29
Arthritis 79
Serositis 52
Renal disease 48
Neurological disorder 6
Hematological manifestation 54
-Leukopenia 41
-Lymphopenia 24
-Thrombocytopenia 24
Immunology 79
-a-DNA 59
ANA 100
ACR, American College of Rheumatology; ANA, anti-nuclear antibodies.
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pH 9.8 containing 50 mM MgCl2 and the absorbance was
measured at 405 nm. S100A8/A9 content of one serum
sample was quantified using a commercial S100A8/A9 kit
(BMA Biomedicals) and used as an internal control. The
values reported are means of duplicates with the back-
ground subtracted and the concentrations were calculated
from titration curves obtained from a pool of normal
human serum.
Real-time PCR
Isolated PBMC from healthy donors were stained with
anti-CD3-Alexa 647, anti-CD19-Pacific Blue, anti-CD14-
PECy7, anti-CD16-FITC, anti-HLA-DR-Alexa 700, anti-
BDCA-1-biotin and anti-BDCA-2-PE antibodies and
sorted on a FACSAria before frozen at -80°C in lysis
buffer. Total RNA was extracted by Purelink RNA mini
Kit (Invitrogen, Carlsbad, CA, USA) and reversely tran-
scribed to cDNA by SuperScript II Platinum synthesis
system (Invitrogen) according to manufacturer’s instruc-
tions. Ribosomal protein L4 (RPL4), S100A8 and
S100A9 mRNA were quantified by real-time PCR using
the SYBR GreenER kit (Invitrogen) in a MYIQ PCR
machine (Bio-Rad, Hercules, CA, USA). The threshold
cycle number and levels of each mRNA were deter-
mined using the formula 2(Rt-Et), where Rt is the
threshold cycle for the housekeeping gene RPL-4 and Et
the threshold cycle for the gene of interest.
Statistics
Data were evaluated with analysis of variance (ANOVA)
when comparing healthy controls with SLE patients or
within the patient cohort when evaluating different dis-
ease manifestations. SAS version 9.2 for Windows XP
(SAS Institute Inc., Cary, NC, USA) was used in the sta-
tistical evaluation. Correlations were calculated by
Spearman rank correlation test without adjustment for
multiple testing. All P-values were considered significant
at P < 0.05.
Results
SLE patients have more activated leukocytes
First, we wanted to confirm abnormalities in PBMCs
from SLE patients described by others to validate our
patient material. Over all, SLE patients had markedly
decreased cell density of PBMCs as compared to healthy
controls (median SLE: 0.41 × 10
6 (0.40 to 0.51) cells/ml
and median healthy controls 1.00 × 10
6 (0.86 to 1.12)
cells/ml, P < 0.0001). A summary of all investigated leu-
kocyte populations is shown in Table 3. SLE patients
had more activated cells with increased HLA-DR
expressing CD4
+ T cells (P = 0.001), CD8
+ T cells (P =
0.02), pro-inflammatory CD16
+ monocytes (P =0 . 0 0 3 )
and percentage of plasma cells (P < 0.0001), as
compared to healthy controls. Altogether we have
demonstrated that SLE patients have more activated leu-
kocytes as compared to healthy controls and these
results are in concordance with previous findings [3,5].
S100A8/A9 is detected on several different cell
populations
Detection of S100A8/A9 has previously been demon-
strated on the surface of monocytes [32] as well as intra-
cellularly in polymorphonuclear cells [28]. We wanted to
see if S100A8/A9 was also present on other cells since
our main objective was to investigate possible aberrant
expression in SLE. We could detect S100A8/A9 on naïve
as well as pro-inflammatory monocytes, PMNs, B cells,
myeloid dendritic cells (mDCs) and pDCs in both SLE
patients and healthy controls (Figure 1). However,
S100A8/A9 could not be detected on T cells where the
mean fluorescence index (MFI) ratio indicated little or
no cell surface S100A8/A9. Levels of the cell surface
S100A8/A9 correlated well in samples from the same
individual between the different cell populations (data
not shown). Treatment with immunosuppressive drugs at
the time of blood sampling was not statistically signifi-
cantly associated with altered cell surface S100A8/A9.
Cell surface S100A8/A9 was not significantly increased in
SLE patients as a whole when compared to healthy con-
trols on any cell population investigated (data not
shown). We then investigated if cell surface S100A8/A9
was altered in patients with active disease (defined as
SLEDAI ≥4) as compared to patients with inactive disease
(SLEDAI < 4). Patients with active disease had increased
cell surface S100A8/A9 on their CD16
+ pro-inflamma-
tory monocytes, pDCs, mDCs as well as PMNs as com-
pared to SLE patients with inactive disease (P = 0.0005,
P = 0.006, P =0 . 0 3a n dP = 0.015, respectively) and
increased cell surface S100A8/A9 on their CD16
+ pro-
inflammatory monocytes and PMNs as compared to
healthy controls (P = 0.0065 and P = 0.034, respectively,
Figure 1). Thus we could demonstrate that cell surface
S100A8/A9 was associated with disease activity and
increased in patients with active disease.
S100A8 and S100A9 are not produced by all leukocytes
Since S100A8/A9 was observed on most cell populations
we wanted to know if this was due to expression of the
S100A8 and S100A9 genes or due to deposition from
external sources. To test the first possibility S100A8 and
S100A9 mRNA levels were analyzed in FACS-sorted
cells. Only low mRNA levels were found in T cells, B
cells and mDCs, despite detection of cell surface
S100A8/A9 on B cells and mDCs. However, clearly
detectable levels of both S100A8 and S100A9 mRNA
were found in monocytes, PMNs and pDCs (Figure 2A).
These results confirm that S100A8/A9 is mainly
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the cell surface S100A8/A9 on other cell populations is
most likely due to external deposition. We could con-
firm our flow cytometry data using confocal microscopy
where we could detect membrane-associated S100A8/
A9 on PMNs, monocytes and pDCs but not on T cells,
mDCs or B cells (Figure 3). However, when using a
non-confocal setting both mDCs and B cells had a weak
S100A8/A9 staining whereas T cells still were negative
(data not shown). In addition, we could detect S100A8/
A9 with intracellular location in PMNs, monocytes and
pDCs further supporting S100A8/A9 protein synthesis
by these cells (Figure 3). Altogether, these data demon-
strate that besides monocytes and PMNs, pDCs are also
able to produce S100A8/A9.
Increased levels of serum S100A8/A9 in SLE
If the presence of S100A8/A9 on the cell surface were
due to external deposition, the level of cell surface
S100A8/A9 might correlate with S100A8/A9 serum con-
centration. We found that S100A8/A9 serum concentra-
tions were clearly increased in SLE as compared to
healthy controls (P < 0.0001, Figure 2B), in accordance
with previous published results [33,34]. Furthermore, we
also found the most pronounced increased serum con-
centrations of S100A8/A9 in patients with arthritis (P =
0.016), as was previously reported [33], as well as in
patients with kidney involvement (P = 0.026). There was
also a statistically significant correlation between serum
concentration of S100A8/A9 and SLEDAI (P < 0.0001, r
= 0.49). However, serum S100A8/A9 level correlated
only with cell surface S100A8/A9 in PMNs (P = 0.027, r
= 0.28) and not cell surface S100A8/A9 levels on other
leukocyte subpopulations. Thus, we could demonstrate
that SLE patients had increased serum levels of S100A8/
A9 which correlated to disease activity, but there were
no strong correlations between S100A8/A9 cell surface
levels and serum levels.
We also investigated whether it was possible to
deposit S100A8/A9 on leukocytes in vitro.N e i t h e r
recombinant S100A8/A9 nor serum containing high
concentrations of S100A8/A9 (> 5,000 ng/ml) gave any
increased surface staining of S100A8/A9 (data not
shown). This might suggest that the S100A8/A9 binding
ligands were already saturated and that other mechan-
isms could also be involved in the deposition of
S100A8/A9 on the cell surface.
Increased pDC cell surface S100A8/A9 upon activation
The flow cytometry data in combination with mRNA
expression and confocal microscopy data strongly sup-
ported that monocytes, PMNs and also pDCs could pro-
duce S100A8/A9. Since the pDC is central in SLE
pathogenesis and S100A8/A9 production is, to our knowl-
edge, previously only described in monocytes and PMNs,
we wanted to further investigate this subpopulation.
When stimulating isolated pDCs with ICs in a serum-free
medium the cell surface S100A8/A9 increased (Figure 2C)
supporting that pDCs are able to synthesize S100A8/A9
and actively transport S100A8/A9 to the cell surface upon
activation. Thus, pDCs could up-regulate cell surface
S100A8/A9 in response to activation and we propose that
pDCs are also able to synthesize S100A8/A9 proteins.
Discussion
SLE is a heterogeneous disease with involvement of vir-
tually all organ systems, including the skin, joints and
kidney. T and B cell activation, production of autoanti-
bodies, formation of ICs and the subsequent tissue
damage if the immune complexes are not handled cor-
rectly are all well described important events in the SLE
pathogenesis. Also, many other cell populations besides
Table 3 Frequencies of different cell populations in SLE patients and healthy controls
Cell population Healthy controls (median and 95% CI)
1 SLE patients (median and 95% CI) P-value
CD3
+ T cells 60.9 (57.8 to 63.9) 65.1 (55.7 to 64.3) 0.42
CD4
+ T cells 62.1 (57.0 to 64.7) 55.2 (51.3 to 58.9) 0.06
CD4
+HLA-DR
+ 6.5 (5.3 to 7.2) 31.3 (24.9 to 36.9) 0.001
CD8
+ T cells 15.7 (14.3 to 18.8) 20.4 (18.6 to 24.0) 0.02
CD8
+HLA-DR
+ 40.8 (39.0 to 43.2) 36.9 (33.4 to 41.5) 0.33
BDCA-1
+ mDCs 0.40 (0.34 to 0.46) 0.31 (0.28 to 0.62) 0.19
BDCA-2
+ pDCs 0.07 (0.07 to 0.11) 0.09 (0.09 to 0.16) 0.39
CD14
++CD16
- monocytes 10.1 (9.6 to 13.3) 16.9 (16.0 to 25.2) 0.013
CD14
++CD16
+ monocytes 0.17 (0.15 to 0.27) 0.30 (0.44 to 0.81) 0.003
CD19
+ B cells 5.6 (4.7 to 6.3) 5.1 (5.0 to 7.8) 0.78
CD19
+CD27
+IgD
-CD38
+CD20
- 0.43 (0.35 to 0.75) 1.0 (0.8 to 3.0) < 0.0001
1For CD3
+ T cells, dendritic cells, monocytes and B cells the percentage is calculated against the total leukocyte count. For all subpopulations, the percentage is
calculated against the main population (for example, CD4
+ T cells for all CD4
+ T cell analyses).
CI, confidence interval; HLA, human leukocyte antigen; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell
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well as in many other studies [3-8,38]. We found that
SLE patients had an increased percentage of plasma
cells as well as increased expression of HLA-DR on
their T cells as demonstrated previously [4-6]. Pro-
inflammatory CD16
+ monocytes have increased poten-
tial to produce pro-inflammatory cytokines such as
TNFa [39] and are increased in inflammatory diseases,
such as rheumatoid arthritis [9]. We could demonstrate
an increased percentage of CD16
+ pro-inflammatory
monocytes also in SLE. Altogether, we have seen patho-
logical changes with increased activation of B cells, T
cells and monocytes in SLE patients and it should be
noted that these very clear cut pathological changes
were also seen in many patients with low disease activ-
ity. Although similar observations have been reported by
others, our cellular analyses serve as a validation of
methods and patient material used in this study. Also, it
Figure 1 Increased cell surface S100A8/A9 in patients with active disease compared with inactive disease and healthy controls.T h e
cell surface S100A8/A9 was determined by flow cytometry on A) CD14
++CD16
+, B) CD14
++CD16
-, C) CD3
+, D) CD19
+, E) CD16+ PMNs, F) BDCA-
1
+ and G) BDCA-2
+ cells. The expression is defined as the mean fluorescence index (MFI) ratio between the S100A8/A9 antibody and its control
isotype antibody in each experiment. The line represents the median-value. Active disease was defined as SLEDAI > 4 (SLE active).
Lood et al. Arthritis Research & Therapy 2011, 13:R60
http://arthritis-research.com/content/13/2/R60
Page 6 of 10is important to assess numbers and activation status of
the different leukocyte populations that we investigate
for S100A8/A9 expression.
Despite the lack of S100A8 and S100A9 mRNA in
many leukocyte subpopulations, cell surface S100A8/A9
was detected by flow cytometry on all of the investigated
cell populations except for T cells. It is known that the
S100A8/A9 complex is produced by phagocytes such as
monocytes and neutrophils [28] and we could verify by
mRNA analyses that, among the cell populations stu-
died, only monocytes, PMNs and also pDCs could pro-
duce S100A8 and S100A9. To our knowledge it has not
previously been shown that pDCs are able to produce
S100A8/A9. Interestingly, S100A8/A9 seemed to be
actively transported to the outside of the membrane
upon pDC activation suggesting that the cell surface
Figure 2 S100A8/A9 mRNA expression in different cell populations, serum levels and cell surface S100A8/A9 upon pDC activation. A)
The relative expression of S100A8 and S100A9 mRNA in different cell populations. PBMCs were isolated and sorted by flow cytometry before
determining the mRNA levels of S100A8 and S100A9 by real-time PCR. B) Serum levels of S100A8/A9 measured by an in-house ELISA in SLE
patients and healthy controls. The line represents the median value. C) Purified pDCs were stimulated with immune complexes for 20 h and
analyzed for cell surface S100A8/A9 by flow cytometry. The data are presented as the mean fluorescence index (MFI) ratio with one standard
deviation as compared to unstimulated cells for each experiment.
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tions. The exact function of S100A8/A9 production in
this particular cell remains to be shown, but the pDCs
as an IFNa producing cell is clearly central in the
pathogenesis of SLE. S100A8/A9 has been suggested to
have several important functions in the immune system
such as activation of monocytes, migration of myeloid
derived suppressor cells and amplification of cytokine
production [29-31,40]. Furthermore, cells from S100A9
deficient mice display reduced TNFa production when
stimulated with LPS, a deficiency that could be restored
by addition of extracellular S100A8/A9 [29]. Also, the
S100A8/A9 complex can increase TNFa production
upon LPS stimulation [29]. Recently, Björk et al. [32]
described that quinoline-3-carboxamides or antibodies
against S100A9 could inhibit the LPS-induced TNFa
production. Recently, Loser et al demonstrated that
S100A8 and S100A9 are crucial for the development of
autoreactive CD8
+ T cells and systemic autoimmunity in
a mouse model [41]. Altogether, this illustrates that
S100A8/A9 could serve as an amplifier of inflammation
and should thus be regarded as a potential target for
treatment of inflammatory diseases such as SLE.
Increased serum levels of S100A8/A9 in SLE, as well
as in other connective tissued i s e a s e ss u c ha sr h e u m a -
toid arthritis and Sjogren’s syndrome, was first described
in 1990 by Kuruto et al. [42] and was later confirmed in
SLE both in serum and by a proteomic-based study on
PBMCs [33,34,43]. We could demonstrate increased
serum concentrations of S100A8/A9 in SLE patients as
compared to healthy controls and a correlation to
disease activity. Cell surface S100A8/A9 was also
increased on several leukocyte subpopulations such as
pDCs in patients with active disease as compared to
patients with inactive disease. However, the cell surface
S100A8/A9 on some leukocyte subpopulations such as
B cells and mDCs could not be explained by protein
synthesis. Furthermore, it has previously been demon-
s t r a t e dt h a te n d o t h e l i a lc e l l sw e r ec o a t e dw i t hc e l ls u r -
face S100A8/A9 but lacked mRNA expression of these
genes [44]. Clearly, other mechanisms also explain why
S100A8/A9 are present on cell surfaces such as ligand
up-regulation and deposition of S100A8/A9 from other
sources such as serum or neutrophil extracellular traps
(NET), which have a high content of S100A8/A9 [45].
High serum levels were, however, not generally asso-
ciated with high cell surface S100A8/A9 levels. Further-
m o r e ,i n c u b a t i o no fS 1 0 0 A 8 / A 9r i c hs e r u mw i t h
leukocytes expressing low levels of S100A8/A9 on their
surface could not increase the cell surface S100A8/A9
suggesting that the ligands most likely were already
saturated. The broad binding pattern of S100A8/A9 to
many cell populations indicates a general binding part-
ner, and heparan sulfate glycosaminoglycans (GAG)
structures and carboxylated glycans have been reported
to bind to the S100A8/A9 complex as well as to the
homodimer S100A9/A9 [44,46]. The low level or
absence of cell surface S100A8/A9 on T cells would
t h e ns u g g e s tas p e c i f i cG A G - s t r u c t u r ee p i t o p en o tp r e -
sent on T cells but otherwise commonly expressed on
most leukocyte populations.
Conclusions
Here we could demonstrate the presence of S100A8/A9
on monocytes and PMNs as well as pDCs, mDCs and B
cells, which are all cells that are important in the
inflammatory response in SLE. We could demonstrate
that pDCs, a cell population believed to be central in
the SLE pathogenesis, could synthesize S100A8/A9 and
express this protein on its surface upon activation. How-
ever, the exact function of S100A8/A9 is not fully
understood and needs further studies. In fact, there are
ongoing clinical trials in SLE performed by us using a
quinoline-3-carboxamide compound targeting S100A9
which will give us more information on the role of
S100A9 blockade in SLE and if it can be used as a ther-
apeutic target.
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Figure 3 Analysis of S100A8/A9 staining in different leukocyte
populations by confocal microscopy. Cells were isolated, fixed,
permeabilized and stained for S100A8/A9 with the 27E10 antibody.
T cells, B cells and mDCs (A, C and E, respectively) had no
detectable S100A8/A9 expression while PMNs, pDCs and monocytes
(B, D and F, respectively) had membrane-associated, as well as
intracellular, S100A8/A9.
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